Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

BACLOFEN

All injection strengths: not a benefit

Other products in the same Health Canada class (M03B, M03BX) — coverage varies; not interchangeable

  • Cyclobenzaprine (Flexeril): not a benefit
  • Tizanidine (Zanaflex): not a benefit
  • Orphenadrine (Norflex): not a benefit

Baclofen Intrathecal · DIN 02485516 · 2mg/mL · injection solution (Preservative-Free)

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Baclofen Intrathecal · DIN 02485516 Manufacturer: Avir Pharma Inc.; listing date 2021-09-30 Health Canada: Marketed since 2021-07-20 · brand BACLOFEN INTRATHECAL · ATC M03BX01 BACLOFEN · form Solution · route Intrathecal · ingredients BACLOFEN 2 MG/ML · company Avir pharma inc. · schedule Prescription
Check this DIN again · Health Canada product record

Baclofen Intrathecal: Formulary list price $35.4500/unit (unit not stated in source; not the patient's cost)

Ministry pays: $35.4500 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97575 · Verify on the e-Formulary ↗ (DIN 02485516)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02485516). DIN 02485516: Baclofen Intrathecal Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 122000023; group id 240; item number 0427; lccId None; manufacturer id AVP Source form: Inj Sol (Preservative-Free); strength: 2mg/mL Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $35.4500; ministry $35.4500 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02485516 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97575
Interchangeable products
Baclofen Injection · DIN 02457075 · $35.4500 Baclofen Injection USP · DIN 02553341 · $35.4500 Baclofen Intrathecal · DIN 02413647 · $35.4500 Lioresal Intrathecal · DIN 02131064 · not recorded
Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02485516
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (12:20 Skeletal Muscle Relaxants) and how they are covered

Matched class: 12:20 Skeletal Muscle Relaxants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DANTROLENE SODIUM 12:20 Skeletal Muscle Relaxants

CYCLOBENZAPRINE HCL

· 12 products · Listed, not a benefit · strengths: 10mg · Tab

TIZANIDINE HCL

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 4mg · Tab

ORPHENADRINE CITRATE

· 2 products · Listed, not a benefit · strengths: 60mg/2mL · Inj Sol-2mL Pk

DANTROLENE SODIUM

· 1 products · General benefit · strengths: 25mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 12:20
Full class listing Related classes: 12:04 Parasympathomimetic (Cholinergic) Agents, 12:08 Parasympatholytic (Cholinergic Blocking) Agents, 12:12 Sympathomimetic (Adrenergic) Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE pms-BACLOFEN (baclofen) is useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis. pms-BACLOFEN may also be of some value in patients with spinal cord injuries and other spinal cord diseases. https://pdf.hres.ca/dpd_pm/00059369.PDF PM date: December 11, 2020 Source product: PMS-BACLOFEN; DIN 02063735; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Baclofen Intrathecal · DIN 02485516 Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02485516

Check this DIN again

Other review policies

For Baclofen Intrathecal: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026